Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers

Next Previous
Trial Profile

A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GC 1118A (Primary)
  • Indications Advanced breast cancer; Appendiceal cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Nasopharyngeal cancer; Oesophageal cancer; Oropharyngeal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors GC Pharma

Most Recent Events

  • 06 May 2024 According to CG Pharmaceuticals media release, the study will be presented at the ASCO Annual Meeting in Chicago, during the Gastrointestinal Cancer session
  • 01 Aug 2020 Status changed to completed.
  • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top